For Patients Full Prescribing Information With Medication Guide IFU Important Safety Information Contact a Representative

Helpful resources for your practice

Clinical materials

Tap to view and download the nurse CINV tracker

Nurse CINV Tracker

Use this checklist at each visit as part of a discussion about CINV to help monitor patients’ experiences.

Tap to view and download SUSTOL Instructions for Use

Instructions for Use (IFU)

A document with information about the preparation and administration of SUSTOL.

Tap to view and download SUSTOL Administration Tear Sheet

Administration Tear Sheet

Illustrated overview and helpful hints to administer SUSTOL.

View tear sheet

MOA and administration videos

MOA Video

Scientific animation that shows how the extended-release 5-HT₃ RA in SUSTOL works.

Administration Video

See how to properly administer SUSTOL.

Patient resources

Tap to view and download the patient CINV symptom tracker

Patient CINV Tracker

Give patients this document to take home to help them keep track of any CINV they experience.

Tap to review the Patient Education Flashcard

Patient Education Flashcard

A flashcard that provides important information about what your patient can expect when receiving SUSTOL.

Click to view English or Spanish versions.

For access and reimbursement resources, please visit HeronConnect.com.

5-HT₃ RA=5-hydroxytryptamine receptor antagonist; CINV=chemotherapy-induced nausea and vomiting; MOA=mechanism of action.

INDICATION

SUSTOL is indicated in combination with other antiemetics in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic chemotherapy (MEC) or anthracycline and cyclophosphamide (AC) combination chemotherapy regimens.

IMPORTANT SAFETY INFORMATION

Contraindications

SUSTOL is contraindicated in patients with hypersensitivity to granisetron, any of the components of SUSTOL, or any other 5-HT₃ receptor antagonist.

Warnings and Precautions

Injection site reactions (ISRs), including infection, bleeding, pain and tenderness, nodules, swelling, and induration, have occurred with SUSTOL. Monitor for ISRs following SUSTOL injection. Inform patients that some ISRs may occur 2 weeks or more after SUSTOL administration. In patients receiving antiplatelet agents or anticoagulants, consider the increased risk of bruising or severe hematoma prior to the use of SUSTOL.

Monitor for constipation and decreased bowel activity and consider optimizing patients’ current bowel regimens used for managing preexisting constipation. Instruct patients to seek immediate medical care if signs and symptoms of ileus occur.

Hypersensitivity reactions have been reported and may occur up to 7 days or longer following SUSTOL administration and may have an extended course. If a reaction occurs, administer appropriate treatment and monitor until signs and symptoms resolve.

Serotonin syndrome has been reported with 5-HT₃ receptor antagonists alone but particularly with concomitant use of serotonergic drugs.

Use in Specific Populations

Avoid SUSTOL in patients with severe renal impairment. In patients with moderate renal impairment, administer SUSTOL not more frequently than once every 14 days.

Adverse Reactions

Most common adverse reactions (≥3%) are injection site reactions, constipation, fatigue, headache, diarrhea, abdominal pain, insomnia, dyspepsia, dizziness, asthenia, and gastroesophageal reflux.

Report side effects to the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. Report side effects to Heron at 1-844-437-6611.

Please see full Prescribing Information, including Medication Guide.